199 related articles for article (PubMed ID: 33734949)
41. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
Rosenthal EM; Hall EW; Rosenberg ES; Harris A; Nelson NP; Schillie S
Vaccine; 2020 Dec; 38(51):8206-8215. PubMed ID: 33160756
[TBL] [Abstract][Full Text] [Related]
42. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.
Aggarwal R; Ghoshal UC; Naik SR
J Hepatol; 2003 Feb; 38(2):215-22. PubMed ID: 12547411
[TBL] [Abstract][Full Text] [Related]
43. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
Mangen MJ; Stibbe H; Urbanus A; Siedenburg EC; Waldhober Q; de Wit GA; van Steenbergen JE;
Vaccine; 2017 May; 35(24):3215-3221. PubMed ID: 28483198
[TBL] [Abstract][Full Text] [Related]
44. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes.
Hoerger TJ; Schillie S; Wittenborn JS; Bradley CL; Zhou F; Byrd K; Murphy TV
Diabetes Care; 2013 Jan; 36(1):63-9. PubMed ID: 22933435
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea.
Lee D; Shin HY; Park SM
Cost Eff Resour Alloc; 2018; 16():6. PubMed ID: 29467596
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load.
Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
Obstet Gynecol; 2014 May; 123(5):929-937. PubMed ID: 24785842
[TBL] [Abstract][Full Text] [Related]
49. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis.
Devine A; Harvey R; Min AM; Gilder MET; Paw MK; Kang J; Watts I; Hanboonkunupakarn B; Nosten F; McGready R
BMC Infect Dis; 2017 Aug; 17(1):552. PubMed ID: 28793866
[TBL] [Abstract][Full Text] [Related]
50. The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis.
Yin J; Ji Z; Liang P; Wu Q; Cui F; Wang F; Liang X; Zhuang G
Vaccine; 2015 Jul; 33(31):3731-8. PubMed ID: 26057138
[TBL] [Abstract][Full Text] [Related]
51. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
Hoshi SL; Seposo X; Okubo I; Kondo M
Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878
[TBL] [Abstract][Full Text] [Related]
53. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
54. Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.
Cheng X; Zhao Y; Zhang X; Jin H; Min J
Hum Vaccin Immunother; 2017 Aug; 13(8):1873-1878. PubMed ID: 28448739
[TBL] [Abstract][Full Text] [Related]
55. [Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China].
Lin Y; Zhang SX; Yang PC; Cai YL; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):852-859. PubMed ID: 28738455
[No Abstract] [Full Text] [Related]
56. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model.
Jing W; Liu J; Wu Y; Ma Q; Liu M
EClinicalMedicine; 2020 Feb; 19():100264. PubMed ID: 32055793
[TBL] [Abstract][Full Text] [Related]
57. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men.
Amirsadri M; Hassani A
Daru; 2015 Dec; 23():56. PubMed ID: 26717884
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
60. Post-vaccination serologic testing of infants born to hepatitis B surface antigen-positive mothers is more cost-effective in Zhejiang Province, China: A Markov chain analysis.
Lu Z; Zhou Y; Yan R; Deng X; Tang X; Zhu Y; Xu X; Zheng W; He H
J Viral Hepat; 2022 Apr; 29(4):280-288. PubMed ID: 35075747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
